Skip to main content

Table 1 Comparison of characteristics between patients with psoriatic arthritis and controls at baseline

From: Serum IL-23 significantly decreased in obese patients with psoriatic arthritis six months after a structured weight loss intervention

 

PsA, n = 41

Controls, n = 39

p-value

Women

26 (63.4)

29 (74.4)

0.424

Age, years

54 (49–62)

55 (46–60)

0.458

Body weight, kg

106.3 (95.8–113.6)

104.6 (96.5–120.0)

0.690

Height, m

1.68 (1.62–1.77)

1.66 (1.62–1.72)

0.190

BMI, kg/m2

35.2 (34.1–38.1)

37.7 (36.7–41.5)

0.001

Waist circumference, cm

116 (112–122)

117 (107–126)

0.817

Current smoking

1 (2.4)

2 (5.1)

0.527

SJC 66, score

0 (0–1)

  

TJC 68, score

4 (1–14)

  

VAS patients´ global disease activity, mm

34 (19–61)

  

VAS pain, mm

30 (19–63)

  

VAS fatigue, mm

56 (22–67)

  

PsO duration, years

32 (19–40)

  

PsA symptoms duration, years

17 (11–27)

  

PsA peripheral disease

35 (85)

  

Axial disease

2 (5)

  

Combination peripheral/axial disease

4 (10)

  

Dactylitis ever

21 (51)

  

DAPSA, score

15.3 (6.6–29.1)

  

DAS28CRP, score

2.9 (2.1–3.7)

  

BSA, %

0.8 (0–2.3)

  

Leeds enthesitis index

1 (0–4)

  

NSAIDs

26 (63)

  

csDMARD without bDMARD

19 (46)

  

bDMARD

16 (39)

  

TNF-inhibitor

15 (37)

  

Methotrexate monotherapy

13 (31.7)

  

Apremilast

1 (2.4)

  

Prednisone

3 (7.3)

  

Ustekinumab monotherapy

1 (2.4)

  

IL-17- and IL-23-inhibitors

0

  

CRP, mg/L

4.0 (2.0–8.5)

4.0 (2.0–6.0)

0.280

Serum concentrations of cytokines and adipokines

 TNF-α, pg/mL

12.92 (9.99–17.20)

11.66 (8.49–13.54)

0.077

 IL-1β, pg/mL

12.86 (6.73–19.69)c

12.13 (5.30–14.81)d

0.399

 IL-6, pg/mL

8.72 (6.23–11.18)

7.23 (5.54–9.47)

0.154

 IL-8, pg/mL

18.69 (13.55–23.21)

19.28 (13.86–27.32)

0.397

 IL-12/IL-23 p40, pg/mL

602.65 (384.93–900.21)a

544.11 (333.38–835.83)c

0.626

 IL-13, pg/mL

906.55 (679.96–1131.63)a

885.07 (650.51–1103.93)b

0.501

 IL-17, pg/mL

2.63 (1.58–4.65)f

0.86 (0.41–3.35)e

0.022

 IL-23, ng/mL

0.40 (0.17–0.54)

0.54 (0.33–0.71)

0.027

 IFN-γ, pg/mL

61.98 (43.73–76.34)

54.73 (43.83–69.95)

0.289

 Resistin, ng/mL

12.83 (10.58–15.77)

11.82 (9.22–16.42)

0.427

 Leptin, ng/mL

26.28 (14.35–48.73)

38.80 (20.47–59.87)

0.059

 HMW adiponectin, µg/mL

3.39 (2.13–5.12)

4.26 (2.07–6.45)

0.384

 Tot-adiponectin, µg/mL

4.03 (3.18–6.06)

4.16 (3.27–5.11)

0.832

  1. Numbers are median (interquartile range) or n (%)
  2. Number of patients with missing data values;
  3. a = 1 b = 2 c = 10 d = 11 e = 19 f = 21
  4. BMI body mass index, BSA body surface area, CRP c-reactive protein, Cs-DMARD conventional synthetic disease modifying anti rheumatic drug, DAPSA disease activity in psoriatic arthritis, DAS28 disease activity score, HAQ health assessment questionnaire, HMW high molecular weight, IFN interferon, IL interleukin, NSAID non-steroidal anti-inflammatory drug, PsA psoriatic arthritis, PsO psoriasis, SJC swollen joint count, TJC tender joint count, TNF tumor necrosis factor, Tot total, VAS visual analogue scale
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us